CHRO (Channel Therapeutics) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Channel Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Channel Therapeutics's Free Cash Flow for the three months ended in Sep. 2024 was $-0.18 Mil. Channel Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Channel Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Channel Therapeutics's current FCF Yield % is -47.84%.

The historical rank and industry rank for Channel Therapeutics's FCF Margin % or its related term are showing as below:

During the past 4 years, the highest FCF Margin % of Channel Therapeutics was -1813.00%. The lowest was -1813.00%. And the median was -1813.00%.

CHRO's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -135.76
* Ranked among companies with meaningful FCF Margin % only.

Channel Therapeutics FCF Margin % Historical Data

The historical data trend for Channel Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Channel Therapeutics FCF Margin % Chart

Channel Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-1,813.00

Channel Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Channel Therapeutics's FCF Margin %

For the Biotechnology subindustry, Channel Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Channel Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Channel Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Channel Therapeutics's FCF Margin % falls into.

Channel Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Channel Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-0.981	/	0
	=	%

Channel Therapeutics's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-0.178	/	0
	=	%

Channel Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Channel Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Channel Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4400 Route 9 South, Suite 1000, Freehold, NJ, USA, 07728

Website

https://www.channeltherapeutics.com

Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Channel Therapeutics Headlines

From GuruFocus

Chromocell Announces Stock Repurchase Plan

By Marketwired • 08-07-2024